Last reviewed · How we verify
NCT03828474: SEAWARDII
Sickness Evaluation at Altitude With Acetazolamide at Relative Doses
Phase 1 trial testing Acetazolamide Pill in Acute Mountain Sickness in 108 participants. Completed in 29 September 2019.
29 September 2019
Quick facts
| Lead sponsor | Stanford University |
|---|---|
| Phase | Phase 1 |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | quadruple |
| Primary purpose | prevention |
| Enrollment | 108 |
| Start date | 9 August 2019 |
| Primary completion | 29 September 2019 |
| Estimated completion | 29 September 2019 |
| Sites | 1 location across United States |
Drugs / interventions tested
- Acetazolamide Pill — full drug profile →
Conditions studied
- Acute Mountain Sickness — all drugs for Acute Mountain Sickness →
Sponsor
Stanford University
Who can join
Adults 18 to 75, any sex, with Acute Mountain Sickness. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The specific aim of this study is to evaluate whether acetazolamide 125mg daily is no worse than acetazolamide 250mg daily in decreasing the incidence of acute mountain sickness (AMS) in travelers to high altitude. The study population is hikers who are ascending at their own rate under their own power in a true hiking environment at the White Mountain Research Station, Owen Valley Lab (OVL) and Bancroft Station (BAR), Bancroft Peak, White Mountain, California
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT03828474
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Acetazolamide Pill
Trials testing the same drug.
- NCT03525561 — Acetazolamide and Exercise Performance at Altitude · EARLY_PHASE1 · completed
Other recruiting trials for Acute Mountain Sickness
Currently open trials in the same condition.
- NCT07126834 — Voluntary Isocapnic Hyperpnea in Hypoxia to Mitigate Acute Mountain Sickness · NA · active not recruiting
- NCT06499714 — HighCycle Study: Effect of High Altitude on Acute Mountain Sickness in Women Related to Their Menstrual Cycle Phase · recruiting
Other Stanford University trials
Trials by the same sponsor.
- NCT05945147 — Ketamine and Midazolam Infusions for CRPS: Feasibility Study · Phase 2 · withdrawn
- NCT04225949 — Patients Understanding of PROM Graphs · NA · withdrawn
- NCT06273098 — School-Based Bladder Health Intervention · NA · withdrawn
- NCT04652635 — Management of Nailbed Injuries · NA · withdrawn
- NCT05443503 — Stanford Spine Keeper - Managing Your Low Back Pain · NA · suspended
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03828474 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Stanford University
- Last refreshed: 22 October 2019
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03828474.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing